07.01.10
#17 - Eisai
4-6-10 Koishikawa, Bunkyo-ku
Tokyo, 112-8088, Japan
Tel: (81) 3 3817 3700
Fax: (81) 3 3811 3077
www.eisai.co.jp
Headcount | 11,415 | |
Year Established | 2005 | |
Pharma Revenues | $8,441 | +11%/+3% |
Total Revenues | $8,658 | +11%/+3% |
Net Income | $435 | -9%/-15% |
R&D Budget | $1,931 | +24%/+15% |
Revenues converted at average exchange rate / based on reported currency (JPY)
2009 Top Selling Drugs | |||
Drug | Indication | Sales | (+/-%) |
Aricept | Alzheimer's disease | $3,480 | +15% |
Aciphex | acid reflux | $1,595 | flat |
Account for 60% of total pharma sales, down from 61% in 2008.
#18 - Otsuka Pharmaceutical
2-9 Kanda-Tsukasamachi, Chiyoda-ku
Tokyo 101-0048 Japan
Tel: (81) (0)3-6717-1410
www.otsuka.com
Headcount | 36,000 | |
Year Established | 1921 | |
Pharma Revenues | $7,717 | +14%/+6% |
Total Revenues | $11,689 | +22%/+13% |
Net Income | $727 | +54%/+43% |
R&D Budget | $1,637 | +20%/+12% |
Revenues converted at average exchange rate / based on reported currency (JPY)
2009 Top Selling Drugs | |||
Drug | Indication | Sales | (+/-%) |
Abilify | anti-psychotic | ||
Mucosta | anti-gastritis, anti-gastric ulcer agent | ||
Pietal | anti-platelet agent |
Otsuka did not provide sales breakdowns for its pharmaceutical products for FY2009.
#19 - Gilead Sciences
333 Lakeside Dr.
Foster City, CA 94404
Tel: (650) 574-3000
Fax: (650) 578-9264
www.gilead.com
Headcount | 3,852 | |
Year Established | 1987 | |
Pharma Revenues | $6,469 | +27% |
Total Revenues | $7,011 | +31% |
Net Income | $2,636 | +33% |
R&D Budget | $940 | +30% |
2009 Top Selling Drugs | |||
Drug | Indication | Sales | (+/-%) |
Truvada | HIV/AIDS | $2,490 | +15% |
Atripla | HIV/AIDS | $2,382 | +52% |
Viread | HIV/AIDS | $668 | +8% |
Ambisome | antifungal | $299 | +3% |
Hepsera | HIV/AIDS | $272 | -20% |
Account for 94% of total pharma sales, down from 97% in 2008.
#20 - Mylan Inc.
1500 Corporate Dr., Ste. 400
Canonsburg, PA 15317
Tel: (724) 514-1800
www.mylan.com
Headcount | 15,500 | |
Year Established | 1961 | |
Pharma Revenues | $5,015 | +8% |
Total Revenues | $5,093 | -1% |
Net Income | $94 | loss of $335 million in 2008 |
R&D Budget | $275 | -13% |
2009 Top Selling Drugs | |||
Drug | Indication | Sales | (+/-%) |
CNS | $1,428 | +16% | |
Cardiovascular | $866 | -3% | |
Anti-infectives | $601 | +32% | |
Other | $494 | +5% | |
Gastrointestinal | $401 | +12% |
Account for 76% of total pharma sales, up from 74% in 2008.
Return to Top Pharma Report homepage.